English
Stock of the day
ResMed
ResMed posts a 9% rise in first-quarter earnings, outlines US manufacturing expansion, and earns strong buy recommendations from analysts, driven by innovation and market share gains.
(AI video summary)
This video was created on 31 October 2025 for IG audiences by ausbiz.
ASX code: RMD
ResMed reports impressive earnings growth
ResMed, a US-based medical device company, which reported a 9% rise in first-quarter (Q1) earnings to US$1.3 billion, with an operating cash flow of $457 million. Net income increased by 12% to $348 million, while gross margins improved by 290 basis points (bp). Revenue was up 8%, driven by 10% growth in the Americas and 6% across Europe, Asia, and other regions.
Expansion plans and dividends
ResMed has also declared a quarterly cash dividend of $0.60 per share. The company is planning to expand its manufacturing operations in the US, signalling confidence in its long-term growth strategy.
Investment outlook
Analysts suggest ResMed as a strong 'buy', citing its earnings growth at a reasonable valuation, trading at 22 times forward earnings with a projected 17% growth rate. Despite concerns over glucagon-like peptide-1 (GLP-1) drugs affecting the Continuous Positive Airway Pressure (CPAP) market, ResMed continues to capture market share.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Contact
New clients
1800 601 799
newaccounts.au@ig.com
Existing clients
1800 601 734
helpdesk.au@ig.com
Lines open
24/7 except 6am to 12pm Saturdays (AEST)
Start a Whatsapp chat
Connect with us
Disclaimers
- CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You do not own or have any interest in the underlying asset. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Please consider the Margin Trading Product Disclosure Statement (PDS), Risk Disclosure Notice and Target Market Determination before entering into any CFD transaction with us.
- The value of shares, ETFs and ETCs bought through an IG share trading account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
- Please ensure you fully understand the risks and take care to manage your exposure.
- The information on this website is prepared without considering your objectives, financial situation or needs. Consequently, you should consider the information in light of your objectives, financial situation and needs.
- This website is operated by IG Australia Pty Ltd. IG Australia Pty Ltd is located on Level 32, Queen & Collins, 376-390 Collins Street, Melbourne, VIC 3000. ABN 93 096 585 410, Australian Financial Services Licence No. 515106. Derivatives Issuer Licence in New Zealand FSP No. 684191, NZBN 9429047618251.